Potentials and challenges of launching the pilot phase of Hong Kong Genome Project

A. Chu, J. Fung, A. Tong, Sin Man Chow, Kelvin Y. K. Chan, Kit San Yeung, H. Lo, B. Chung
{"title":"Potentials and challenges of launching the pilot phase of Hong Kong Genome Project","authors":"A. Chu, J. Fung, A. Tong, Sin Man Chow, Kelvin Y. K. Chan, Kit San Yeung, H. Lo, B. Chung","doi":"10.20517/jtgg.2022.02","DOIUrl":null,"url":null,"abstract":"Genomic medicine and precision medicine initiatives have taken centre stage in scientific, clinical, as well as health economics and utility research on the global scene for the past decade. It is clear the important role genomic advancement has played in enhancing diagnostic rate, streamlining personalised treatment, and improving efficacy of the overall clinical management of undiagnosed, rare, and common diseases for humankind. The Hong Kong Genome Institute (HKGI) was established in May 2020 within the Food and Health Bureau, Hong Kong Special Administrative Region, to integrate genomic medicine into mainstream healthcare. The main goals of setting up HKGI are to (1) improve the diagnostic rate and future care for individuals affected by undiagnosed diseases and hereditary cancers using whole genome sequencing; (2) advance research in genomic science; (3) nurture talents in genomic medicine; and (4) enhance public genomic literacy and overall engagement through the launching of the Hong Kong Genome Project (HKGP). In this paper, we review the current landscape and specific challenges encountered during the construction of the infrastructure and implementation of the pilot phase of HKGP. Through reviewing what has been achieved and established to date, and the potentials and prospects that have emerged in the process, this paper will provide insights into planning the main phase of HKGP, and considerations for our international counterparts when building similar projects.","PeriodicalId":73999,"journal":{"name":"Journal of translational genetics and genomics","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of translational genetics and genomics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20517/jtgg.2022.02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Genomic medicine and precision medicine initiatives have taken centre stage in scientific, clinical, as well as health economics and utility research on the global scene for the past decade. It is clear the important role genomic advancement has played in enhancing diagnostic rate, streamlining personalised treatment, and improving efficacy of the overall clinical management of undiagnosed, rare, and common diseases for humankind. The Hong Kong Genome Institute (HKGI) was established in May 2020 within the Food and Health Bureau, Hong Kong Special Administrative Region, to integrate genomic medicine into mainstream healthcare. The main goals of setting up HKGI are to (1) improve the diagnostic rate and future care for individuals affected by undiagnosed diseases and hereditary cancers using whole genome sequencing; (2) advance research in genomic science; (3) nurture talents in genomic medicine; and (4) enhance public genomic literacy and overall engagement through the launching of the Hong Kong Genome Project (HKGP). In this paper, we review the current landscape and specific challenges encountered during the construction of the infrastructure and implementation of the pilot phase of HKGP. Through reviewing what has been achieved and established to date, and the potentials and prospects that have emerged in the process, this paper will provide insights into planning the main phase of HKGP, and considerations for our international counterparts when building similar projects.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
启动香港基因组计划试验阶段的潜力和挑战
过去十年来,基因组医学和精准医学倡议在全球范围内的科学、临床以及卫生经济学和实用研究中占据了中心位置。很明显,基因组学的进步在提高诊诊率、简化个性化治疗和提高人类未确诊、罕见和常见疾病的整体临床管理效率方面发挥了重要作用。香港基因组研究所(HKGI)成立于2020年5月,隶属于香港特别行政区食物及卫生局,旨在将基因组医学纳入主流医疗保健。设立香港基因组的主要目的是:(1)利用全基因组测序提高未确诊疾病和遗传性癌症患者的诊断率和未来护理;(2)推进基因组科学研究;(3)培养基因组医学人才;(4)透过推出“香港基因组计划”,提高公众对基因组的认知和整体参与。在本文中,我们将回顾香港政府在基础设施建设和试行阶段所遇到的具体挑战。本文将回顾香港旅游计划至今所取得的成就,以及在此过程中出现的潜力和前景,为规划香港旅游计划的主要阶段提供见解,并为国际同行在建设类似项目时提供参考。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.70
自引率
0.00%
发文量
0
期刊最新文献
Duchenne muscular dystrophy: diagnosis and perspective of treatment Challenges in determining the malignant potential of atypical neurofibromas (aNF) using histopathologic features and the potential need for CDKN2A/2B testing: a case report Genetics in the diagnosis and treatment of cardiovascular diseases Silent players, loud impact: unveiling the therapeutic potentials of LncRNAs Reduced protein kinase C delta in a high molecular weight complex in mitochondria and elevated creatine uptake into Barth syndrome B lymphoblasts.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1